Company intelligence
Eclipsebio
Next-generation assays. Data-driven analytics. RNA breakthroughs.
About Eclipsebio
Eclipsebio develops first-in-class technologies, analyses, and platforms for the development of tomorrow’s RNA-based and RNA-targeting therapies. With our extensive experience in supporting early-stage basic research to evaluating preclinical vaccines and gene therapies, we provide unparalleled support for obtaining deep insights into RNA and therapeutic biology. We offer our solutions as end-to-end partnerships, including RNA design and custom assay development, for biopharma and biotech companies and as a la carte services. Our areas of support include: • RNA therapeutic sequence design informed by biological data through our eNAVIGATE platform • The optimization and characterization of RNA-based vaccines and therapeutics through our eMERGE platform • Multiomic characterization of small molecule and small oligonucleotide targets • Robust validation of on-target, and the identification of off-target, effects from small molecule and small oligonucleotide drugs • Deep profiling of RNA for groundbreaking discoveries in academic research Contact us today to discover how we can provide you with the insights needed for RNA success.
Verified activity
Signals from Eclipsebio
4 published signals
Research & Knowledge
Eclipsebio is posting a weekly series on what standard QC is missing, including RNA integrity and sequencing-based assays like eSENSE Break and eSTRAND RNA QC.
Reported by Eclipsebio
Research & Knowledge
Eclipsebio published a review by Ojalvo et al. describing the process of individualized neoantigen therapy across three phases involving formalin-fixed paraffin-embedded tumor blocks, whole blood for germline control and HLA typing, and a CAP/CLIA- and ISO13485-certified lab for histopathology, nucleic acid extraction, and next-generation sequencing.
Reported by Eclipsebio
Research & Knowledge
Eclipsebio researcher Raza et al. used RBP-eCLIP to find that ECD binds near splice sites and to U5 snRNA to regulate U5 snRNP expression.
Reported by Eclipsebio
Products & Services
Eclipsebio launched eSTRAND RNA QC, a multi-attribute nanopore-based RNA characterization assay using direct sequencing to read full-length RNA without reverse transcription or translation.
Reported by Eclipsebio